KOD I A K S C I E N C E S I N C . FORWARD-LOOKING STATEMENTS ÁǝǣɀƬȒȅȅɖȇǣƬƏɎǣȒȇƬȒȇɎƏǣȇɀٹǔȒȸɯƏȸƳٮǼȒȒǸǣȇǕɀɎƏɎƺȅƺȇɎɀٺɯǣɎǝǣȇɎǝƺȅƺƏȇǣȇǕȒǔ³ƺƬɎǣȒȇואȒǔɎǝƺ³ƺƬɖȸǣɎǣƺɀ Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities nǣɎǣǕƏɎǣȒȇ«ƺǔȒȸȅƬɎȒǔِדחח׏ÁǝƺɀƺǔȒȸɯƏȸƳٮǼȒȒǸǣȇǕɀɎƏɎƺȅƺȇɎɀ ƏȸƺȇȒɎƫƏɀƺƳȒȇǝǣɀɎȒȸǣƬƏǼǔƏƬɎƏȇƳǣȇƬǼɖƳƺ ɀɎƏɎƺȅƺȇɎɀȸƺǕƏȸƳǣȇǕيk³Xټ׏׎׏ٮɀȵȒɎƺȇɎǣƏǼɎȒƫƺƬȒȅƺƏƬȒȸȇƺȸɀɎȒȇƺɎǝƺȸƏȵɵǔȒȸx0³XٕkȒƳǣƏǸټɀȵǼƏȇȇƺƳ nˡǼǣȇǕٕ the ABC Platform’s potential to enable differentiated, disease-modifying medicines across vision-threatening ƳǣɀƺƏɀƺɀٕkȒƳǣƏǸټɀƺɴȵǼȒȸƏɎǣȒȇȒǔƫȸȒƏƳƺȸɖɀƺɀȒǔɎǝƺà0ÁǣɎƺƬǝ ȇȒǼȒǕɵًǣȇƬǼɖƳǣȇǕǣȇǣƳƺȇɎǣɎɵɀƺƬɖȸǣɎɵƏȇƳƬȒǕȇǣɎǣɮƺ science, and belief that it has the potential to become an important part of how Kodiak builds value over the long term. Forward-looking statements generally include statements that are predictive in nature and depend upon ȒȸȸƺǔƺȸɎȒǔɖɎɖȸƺƺɮƺȇɎɀȒȸƬȒȇƳǣɎǣȒȇɀًƏȇƳǣȇƬǼɖƳƺɯȒȸƳɀɀɖƬǝ ƏɀٹƏȇɎǣƬǣȵƏɎƺًٺٹƫƺǼǣƺɮƺًٺٹƬȒɖǼƳًٺٹƺɴȵƺƬɎًٺٹǣȇɎƺȇƳًٺ ٹȅƏɵًٺٹȵǼƏȇًٺٹȵɖȸɀɖƺًٺٹɀǝȒɖǼƳًٺٹɯǣǼǼًٺٹɯȒɖǼƳًٺƏȇƳȒɎǝƺȸɀ ǣȅǣǼƏȸƺɴȵȸƺɀɀǣȒȇɀًƏȅȒȇǕȒɎǝƺȸɀِȇɵǔȒȸɯƏȸƳٮǼȒȒǸǣȇǕ statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied ƫɵɀɖƬǝǔȒȸɯƏȸƳٮǼȒȒǸǣȇǕɀɎƏɎƺȅƺȇɎɀِÁǝƺɀƺȸǣɀǸɀƏȇƳɖȇƬƺȸɎƏǣȇɎǣ ƺɀǣȇƬǼɖƳƺًƫɖɎƏȸƺȇȒɎǼǣȅǣɎƺƳɎȒيɎǝƺȸǣɀǸɎǝƏɎɎǝƺ ƬȒȅȵǼƺɎƺƳ ̈ǝƏɀƺבɀɎɖƳǣƺɀǔȒȸñƺȇǸɖƳƏȅƏɵȇȒɎƫƺɀɖǔˡƬǣƺȇɎɎȒɀɖȵȵȒȸɎƏ nɀɖƫȅǣɀɀǣȒȇȒȸƏȵȵȸȒɮƏǼǣȇƳǣƏƫƺɎǣƬ retinopathy, retinal vein occlusion, or wet AMD; the risk that a BLA for tarcocimab tedromer or any other product candidate may not be accepted by, or receive approval from, the FDA or foreign regulatory agencies when expected, ȒȸƏɎƏǼǼٕɎǝƺȸǣɀǸɎǝƏɎƬƺɀɀƏɎǣȒȇًȅȒƳǣˡƬƏɎǣȒȇًȒȸƳƺǼƏɵȒǔƏȇɵȒȇǕȒǣȇǕƬǼǣȇǣƬƏǼɀɎɖƳǣƺɀƏȇƳkȒƳǣƏǸټɀƳƺɮƺǼȒȵȅƺȇɎȒǔ ñƺȇǸɖƳƏًk³Xً׏׎דٮk³Xً׏׎׏ٮȒȸƏȇɵȒɎǝƺȸȵȸȒƳɖƬɎƬƏȇƳǣƳƏɎƺȅƏɵȒ ƬƬɖȸٕɎǝƺȸǣɀǸɎǝƏɎɀƏǔƺɎɵًƺǔˡƬƏƬɵًƏȇƳƳɖȸƏƫǣǼǣɎɵƳƏɎƏ observed in Kodiak’s product candidates in current or prior studies may not continue or persist; the risk that KSI-501 may not inhibit VEGF and IL-6 or have an impact on the treatment of patients as expected, and that preclinical data suggesting the possibility that KSI-501 may be a disease-modifying therapy may not translate to clinical outcomes; the risk that the DAYBREAK Phase 3 study for Zenkuda or KSI-501 may not achieve its primary endpoint or may not do so on the anticipated timeline; the risk that the PEAK Phase 3 study for KSI-101 may not achieve its primary endpoint or may not do so on the anticipated timeline; the risk that any one or more of Kodiak’s product candidates may not ƫƺɀɖƬƬƺɀɀǔɖǼǼɵƳƺɮƺǼȒȵƺƳًƏȵȵȸȒɮƺƳًȒȸƬȒȅȅƺȸƬǣƏǼǣɿƺƳٕɎǝƺȸǣɀǸɎǝƏɎkȒƳǣƏǸټɀȸƺɀƺƏȸƬǝƏȇƳƳƺɮƺǼȒȵȅƺȇɎƺǔǔȒȸɎɀƏȇƳ ƏƫǣǼǣɎɵɎȒƏƳɮƏȇƬƺȵȸȒƳɖƬɎƬƏȇƳǣƳƏɎƺɀǣȇɎȒǼƏɎƺȸɀɎƏǕƺɀȒǔƳƺɮƺǼȒȵȅƺȇɎȅƏɵǔƏǣǼٕɎǝƺȸǣɀǸɎǝƏɎɀɖǔˡƬǣƺȇɎƬƏȵǣɎƏǼȅƏɵ not be available as expected, or at all, to complete the development of any products; adverse conditions in the general ƳȒȅƺɀɎǣƬƏȇƳǕǼȒƫƏǼƺƬȒȇȒȅǣƬȅƏȸǸƺɎɀًɯǝǣƬǝȅƏɵɀǣǕȇǣˡƬƏȇɎǼɵǣȅ ȵƏƬɎkȒƳǣƏǸټɀƫɖɀǣȇƺɀɀƏȇƳȒȵƺȸƏɎǣȒȇɀًǣȇƬǼɖƳǣȇǕ ǣɎɀƬǼǣȇǣƬƏǼɎȸǣƏǼɀǣɎƺɀًƏɀɯƺǼǼƏɀɎǝƺƫɖɀǣȇƺɀɀȒȸȒȵƺȸƏɎǣȒȇɀȒǔǣɎɀȅƏȇɖǔƏƬɎɖȸƺȸɀًƬȒȇɎȸƏƬɎȸƺɀƺƏȸƬǝȒȸǕƏȇǣɿƏɎǣȒȇɀًȒȸ ȒɎǝƺȸɎǝǣȸƳȵƏȸɎǣƺɀɯǣɎǝɯǝȒȅkȒƳǣƏǸƬȒȇƳɖƬɎɀƫɖɀǣȇƺɀɀٕƏɀɯƺǼǼƏɀɎǝƺȒɎǝƺȸȸǣɀǸɀǣƳƺȇɎǣˡƺƳǣȇɎǝƺɀƺƬɎǣȒȇƺȇɎǣɎǼƺƳ ٹ«ǣɀǸIƏƬɎȒȸɀٺǣȇkȒƳǣƏǸټɀȇȇɖƏǼ«ƺȵȒȸɎȒȇIȒȸȅٮ׎׏kǔȒȸɎǝƺɵƺƏȸƺȇƳƺƳ(ƺƬƺȅƫƺȸً׏בًדא׎אƏɀɯƺǼǼƏɀƳǣɀƬɖɀɀǣȒȇɀ ȒǔȵȒɎƺȇɎǣƏǼȸǣɀǸɀًɖȇƬƺȸɎƏǣȇɎǣƺɀًƏȇƳȒɎǝƺȸǣȅȵȒȸɎƏȇɎǔƏƬɎȒȸɀǣȇkȒƳǣƏǸټɀɀɖƫɀƺȷɖƺȇɎˡǼǣȇǕɀɯǣɎǝɎǝƺ³ƺƬɖȸǣɎǣƺɀƏȇƳ 0ɴƬǝƏȇǕƺ!ȒȅȅǣɀɀǣȒȇِÁǝƺɀƺǔȒȸɯƏȸƳٮǼȒȒǸǣȇǕɀɎƏɎƺȅƺȇɎɀɀȵƺƏǸȒȇǼɵƏɀȒǔɎǝƺƳƏɎƺȒǔɎǝǣɀƬȒȅȅɖȇǣƬƏɎǣȒȇًƏȇƳ Kodiak undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are cautioned not to place undue reliance on such forward-looking statements.